New fabry drug shows promise in small switch study
NCT ID NCT05843916
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested a new version of the drug agalsidase beta (AGA BETA BS) in 20 people with Fabry disease who were already stable on the standard drug Fabrazyme. Participants switched to the new drug for 54 weeks to see if it worked just as well. The main goal was to keep a key disease marker (Lyso-Gb3) at the same level.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
agalsidase beta (AGA BETA BS)
What this could lead to
If successful, this could provide an alternative treatment option for Fabry disease patients currently on Fabrazyme.
What could go wrong
This is a small, early-stage trial with only 20 participants. It tests a biosimilar, not a new drug, so the benefits may be similar to existing treatment. Risks include infusion reactions or lack of long-term safety data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Médico Santa María de la Salud
San Isidro, Buenos Aires, 1642, Argentina
-
Centro Oncológico Riojano Integral
La Rioja, F5300, Argentina
-
Clínica Universitaria Reina Fabiola
Córdoba, X5004, Argentina
-
Instituto de Investigaciones Clínicas Quilmes
Buenos Aires, Argentina
-
Instituto de Nefrología Pergamino S.R.L
Pergamino, Buenos Aires, 2700, Argentina